Latest news with #JoshuaH.Grabar
Associated Press
29-05-2025
- Business
- Associated Press
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); Maison Solutions, Inc. (NASDAQ: MSS); Manhattan Associates, Inc. (NASDAQ: MANH); and Monolithic Power Systems, Inc. (NASDAQ: MPWR)
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- DoubleVerify Holdings, Inc. (NYSE: DV): If you have held DoubleVerify Holdings, Inc. (NYSE: DV) shares since prior to November 10, 2023, and would like to learn more about the investigation and your rights, please visit contact Joshua Grabar at [email protected], or call us at 267-507-6085. Grabar Law Office is investigating whether officers and directors of DoubleVerify breached their fiduciary duties owed to the company. Why? As alleged in an underlying securities fraud class action complaint, DoubleVerify, via certain of its officers, failed to disclose that: (a) DoubleVerify's customers were shifting their ad spending from open exchanges to closed platforms, where the Company's technological capabilities were limited and competed directly with native tools provided by platforms like Meta Platforms and Amazon; (b) DoubleVerify's ability to monetize on Activation Services, the Company's high-margin advertising optimization services segment, was limited because the development of its technology for closed platforms was significantly more expensive and time-consuming than disclosed to investors; (c) DoubleVerify's Activation Services in connection with certain closed platforms would take several years to monetize; (d) DoubleVerify's competitors were better positioned to incorporate AI into their offerings on closed platforms, which impaired DoubleVerify's ability to compete effectively and adversely impacted the Company's profits; (e) DoubleVerify systematically overbilled its customers for ad impressions served to declared bots operating out of known data center server farms; (f) DoubleVerify's risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities; and (g) as a result of the above, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. What You Can Do Now: Current DoubleVerify shareholders who have held DoubleVerify shares since prior to November 10, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit contact Joshua H. Grabar at [email protected], or call 267-507-6085. Maison Solutions Inc. (NASDAQ: MSS) Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Maison Solutions Inc. (NASDAQ: MSS) as an underlying securities fraud class action has survived a motion to dismiss the complaint. If you are a current Maison Solutions Inc. (NASDAQ: MSS) shareholder who purchased Maison shares on or near its October 5, 2023 IPO, you can seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit contact Joshua Grabar at [email protected] or call us at 267-507-6085 WHY? An underlying securities fraud class action complaint alleges that in Maison Solutions Inc.'s (NASDAQ: MSS) IPO Registration Statement and throughout the Class Period (October 5, 2023 through December 15, 2023), Maison, through certain of its officers, made materially false and/or misleading statements, including failing to disclose to investors: (1) that the Company's vendor XHJC Holdings Inc., is a related party; (2) that the Company's CEO and related entities were alleged to have used supermarkets as a front to defraud the EB-5 visa program; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On March 31, 2025, material portions of the underlying securities fraud complaint survived a motion to dismiss. WHAT YOU CAN DO NOW: If you purchased Maison Solutions Inc. (NASDAQ: MSS) shares on or near its October 5, 2023 IPO and still hold shares today, you are encouraged to visit contact Joshua Grabar at [email protected], or call 267-507-6085. You may be able to seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $MSS #MaisonSolutions Manhattan Associates, Inc. (NASDAQ: MANH): Grabar Law Office is investigating whether certain officers and directors of Manhattan Associates, Inc. (NASDAQ: MANH) breached their fiduciary duties owed to the company. If you have held Manhattan Associates, Inc. (NASDAQ: MANH) shares since prior to October 22, 2024, and would like to learn more about the investigation and your rights, please visit contact Joshua Grabar at [email protected], or call us at 267-507-6085. Why? A recently filed securities fraud class action complaint alleges that Manhattan Associates, Inc. (NASDAQ: MANH), through certain of its officers, provided investors with material information concerning Manhattan Associates' expected revenue for the fiscal year 2025. These statements included, among other things, confidence in the Company's ability to forecast guidance despite macroeconomic fluctuations, the growth potential of their professional services offerings, and the ability for their cloud revenue to drive revenue for its professional services. The underlying complaint alleges that Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Manhattan Associates' forecasting ability for its professional services; notably, the Company was either not truly equipped to deliver 'responsible targets' for growth or, otherwise, Manhattan Associates' services were not equipped to achieve such targets. Finally, the Complaint alleges that such statements absent these material facts caused Plaintiff and other shareholders to purchase Manhattan Associates' securities at artificially inflated prices. What You Can Do Now: Current Manhattan Associates shareholders who have held Manhattan Associates shares since prior to October 22, 2024, are encourage to visit contact Joshua H. Grabar at [email protected], or call us at 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $MANH #ManhattanAssociates Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office is investigating claims on behalf of Monolithic Power Systems, Inc. (NASDAQ: MPWR) shareholders. The investigation concerns whether certain officers and directors of Monolithic have breached their fiduciary duties owed to the company. Current Monolithic (NASDAQ: MPWR) shareholders who have held shares of the Company's stock since prior to February 8, 2024, can seek corporate reforms, the return of funds back to the company, and potentially a court approved incentive award if appropriate, at no cost to them whatsoever. Click here to learn more: contact Joshua Grabar at [email protected], or call us at 267-507-6085. WHY: A recently filed securities fraud class action Complaint alleges that, Monolithic Power Systems, Inc. (NASDAQ: MPWR), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) Monolithic's voltage regulator modules and power management integrated circuits were suffering from significant performance and quality control issues; (ii) these defects had, in turn, negatively impacted the performance of certain products offered by Nvidia in which such products were used; (iii) Monolithic had failed to adequately address and resolve known issues affecting the performance of the power management solutions Monolithic supplied to Nvidia; (iv) Monolithic's relationship with Nvidia - the Company's most important customer - had been irreparably damaged due to the significant performance and quality control problems affecting the products it supplied to Nvidia and Monolithic's failure to adequately address such issues; and (v) as a result of the above, Monolithic was acutely exposed to material undisclosed risks of significant business, financial, and reputational harm. WHAT YOU CAN DO NOW: If you have held Monolithic (NASDAQ: MPWR) shares since prior to February 8, 2024, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever. Please visit contact Joshua Grabar at [email protected], or call us at 267-507-6085. #MonolithicPower #MPWR $MPWR Attorney Advertising Disclaimer Contact: Joshua H. Grabar, Esq. Grabar Law Office One Liberty Place 1650 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: 267-507-6085 Email: [email protected]
Associated Press
06-05-2025
- Business
- Associated Press
Attention Long-Term Shareholders of Integra LifeSciences Holdings Corporation (NASDAQ
PHILADELPHIA, May 06, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corp. (NASDAQ: IART): Current Integra LifeSciences Holdings Corp. (NASDAQ: IART) shareholders who have held the stock since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them. Learn more or join at: . Contact Joshua H. Grabar at [email protected] , or call 267-507-6085. WHY: An underlying securities fraud class action complaint alleges that Integra, via certain of his officers and directors, repeatedly touted that it was on track to grow SurgiMend's market by obtaining FDA approval for use in post-mastectomy reconstruction, yet on May 23, 2023, the Company was forced to announce a 'recall' of all products manufactured at its Boston Facility between March 1, 2018 and May 22, 2023. Integra LifeSciences explained that it had determined that the Boston Facility deviated from good manufacturing practices in testing for bacterial endotoxin and allowed the release of products with unsafe levels of endotoxins. As a result of the recall and manufacturing shutdown, the Company revised its guidance for the second quarter of 2023, lowering its revenue expectations by and disclosed that it expected to take a $22 million impairment due to the inventory write-off. WHAT TO DO NOW: Current Integra LifeSciences shareholders who have held Integra LifeSciences shares since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit , contact Joshua H. Grabar at [email protected] , or call us at 267-507-6085. $IART #IntegraLifeSciences Mercury Systems, Inc. (NASDAQ: MRCY) Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of Mercury Systems, Inc. (NASDAQ: MRCY) shareholders as securities fraud class action complaint partially survives motion to dismiss. . Current Mercury Systems shareholders who have held shares since prior to February 3, 2021, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. To learn more or join click here: , contact Joshua H. Grabar at [email protected] , or call us at 267-507-6085. WHY: A recently filed securities fraud class action complaint has now partially survived defendants' attempts to dismiss that complaint. The underlying complaint alleges that Mercury Systems, through certain of its officers and directors, used acquisitions and improper revenue recognition practices to mask its inability to grow organically. The complaint further alleges that Defendants repeatedly misled investors to believe that their growth was organic by misrepresenting several elements of Mercury's business, including by hiding that Mercury had switched from 'point-in-time' to 'long-term contracts' in order to improperly boost reported revenues and that several of Mercury's projects were in significant distress, including projects related to Mercury's acquisition of Physical Optics Corporation. Finally, the Complaint alleges Mercury also lied to investors about its strategic growth initiative, 1MPACT, which was designed to improve profit margins but unbeknownst to investors was used to disguise regular expenses as restructuring costs, enabling Mercury to claim that recurring expenses were one-time costs. On February 20, 2025, a Federal Court determined that certain key allegations in the plaintiff's underlying securities fraud class action complaint were adequately pleaded to survive defendants attempts to dismiss the complaint. WHAT YOU CAN DO NOW: If you have held Mercury Systems shares since prior to February 3, 2021, and would like to learn more about this matter, you are encouraged to visit , contact Joshua H. Grabar at [email protected] , or call us at 267-507-6085. $MRCY #MercurySystems Monolithic Power Systems, Inc. (NASDAQ: MPWR): Current Monolithic Power Systems, Inc. (NASDAQ: MPWR) shareholders who have held shares of the Company's stock since prior to February 8, 2024, can seek corporate reforms, the return of funds back to the company, and potentially a court approved incentive award if appropriate, at no cost to them whatsoever. Click here to learn more or join: , contact Joshua Grabar at [email protected] , or call us at 267-507-6085. WHY: A recently filed securities fraud class action Complaint alleges that, Monolithic Power Systems, Inc. (NASDAQ: MPWR), via certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) Monolithic's voltage regulator modules and power management integrated circuits were suffering from significant performance and quality control issues; (ii) these defects had, in turn, negatively impacted the performance of certain products offered by Nvidia in which such products were used; (iii) Monolithic had failed to adequately address and resolve known issues affecting the performance of the power management solutions Monolithic supplied to Nvidia; (iv) Monolithic's relationship with Nvidia - the Company's most important customer - had been irreparably damaged due to the significant performance and quality control problems affecting the products it supplied to Nvidia and Monolithic's failure to adequately address such issues; and (v) as a result of the above, Monolithic was acutely exposed to material undisclosed risks of significant business, financial, and reputational harm. WHAT YOU CAN DO NOW: If you have held Monolithic (NASDAQ: MPWR) shares since prior to February 8, 2024, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever. Please visit , contact Joshua Grabar at [email protected] , or call us at 267-507-6085. #MonolithicPower #MPWR $MPWR Virtu Financial Inc. (NASDAQ: VIRT) Class Action Survives Motion to Dismiss: A federal securities fraud class action complaint alleging that Virtu Financial Inc. (NASDAQ: VIRT), and certain of its officers failed to disclose to investors that it had improper safeguards in place for sensitive trader information, has survived a motion to dismiss. Virtu shareholders who have continuously held Virtu shares since prior to November 7, 2018, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Learn more or join by clicking , contact Joshua H. Grabar at [email protected] , or call 267-507-6085. WHY: A securities fraud class action complaint alleges that Virtu Financial (NASDAQ: VIRT), via certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) the Company maintained deficient policies and procedures with respect to its information access barriers; (ii) accordingly, Virtu had overstated the Company's operational and technological efficacy as well as its capacity to block the exchange of confidential information between departments or individuals within the Company; (iii) the foregoing deficiencies increased the likelihood that the Company would be subject to enhanced regulatory scrutiny; and (iv) as a result, Defendants' public statements were materially false and/or misleading at all relevant times. On March 17, 2025, a federal Court determined that key allegations were sufficiently pled to survive defendants' motion to dismiss. According to the Court's Order, 'essentially anyone at Virtu, including its proprietary traders' could directly access this material non-public information from at least January 2018 through April 2019, and to do so, Virtu traders only needed to use a 'widely known and frequently shared username and password.' WHAT YOU SHOULD DO NOW: If you are a current Virtu shareholder who has held Virtu stock since on or before November 7, 2018, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever. If you would like to learn more about this matter, you are encouraged visit , contact Joshua H. Grabar at [email protected] or call 267-507-6085. $VIRT #VirtuFinancial Attorney Advertising Disclaimer Contact: Joshua H. Grabar, Esq. Grabar Law Office One Liberty Place 1650 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: 267-507-6085 Email: [email protected]
Associated Press
17-04-2025
- Business
- Associated Press
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); NAPCO Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)
PHILADELPHIA, April 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) If you have held BioAge Labs, Inc. (NASDAQ: BIOA) shares continuously since on or shortly after its September 26, 2024 IPO, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit contact Joshua H. Grabar at [email protected] or call 267-507-6085 to learn more. Why? BioAge completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share. However, less than three months later, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelapgrag. In response to the news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024. Following this news, a federal securities fraud class action complaint was filed in which it is alleged that BioAge and ten of its Officers and Directors made materially false and/or misleading statements in its initial public offering concerning its STRIDES Phase 2 clinical trial and that these investors sustained damages as a result thereof. Specifically, it is alleged that BioAge's final prospectus for its IPO represented the significance and benefits of azelaprag for the treatment of obesity in older adults. Defendants touted BioAge's lead product candidate azelaprag in connection with the Company's ongoing STRIDES with expectations of topline results in 2025. Defendants also mentioned its collaboration with Lilly's Chorus clinical development organization who would be advising and assisting on all aspects of the STRIDES trial design and execution. Defendants further discussed the potential for a second Phase 2 clinical trial combining azelaprag and semaglutide to treat obesity in individuals ages 18 years and older. Therefore, the initial public offering represented to the public that there were no safety concerns and the Company expected top line results and to meet its primary endpoint goals in connection with its STRIDES clinical trial. Contrary to these representations, BioAge discontinued the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after several subjects showed elevated levels of liver enzymes warning of potential organ damage. As a result, Defendants discontinued the clinical trial and halted further enrollment. Given the fact that Defendants failure to disclose the potential for liver transaminitis in any of its previous clinical Phase 1 trials and various preclinical tox studies, Defendants' statements in BioAge's registration statement were allegedly false and/or materially misleading at the time of the initial public offering. What You Can Do Now? Current BioAge shareholders who have held BioAge shares since on or shortly after its September 26, 2024 IPO, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit contact us at [email protected], or call 267-507-6085. #BioAge $BIOA NAPCO Security Technologies, Inc. (NASDAQ: NSSC) Class Action Survives Motion to Dismiss If you are a Current NAPCO (NASDAQ: NSSC) shareholder who has held NAPCO shares since prior to November 7, 2022, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Click here to join or learn more: contact Joshua H. Grabar at [email protected], or call 267-507-6085. Why? Key allegations in a recently filed securities fraud class action complaint have survived a motion to dismiss. That complaint alleges that NAPCO Security Technologies, Inc. (NASDAQ: NSSC), through certain of its officers and directors, made materially false and/or misleading statements and/or failed to disclose that: (1) NAPCO failed to address any material weaknesses with internal controls regarding cost of goods sold ('COGS') and inventory; (2) NAPCO downplayed the severity of material weaknesses regarding their internal controls; (3) NAPCO's unaudited financial statements from September 30, 2022 to the present included 'certain errors' such as overstating inventory and understanding net COGS, resulting in overstated gross profit, operating income and net income for each period; (4) as a result, NAPCO would need to restate its previously filed unaudited financial statements for certain periods; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. On April 11, 2025, the federal court determined that key allegations would survive Defendants' motion to dismiss the complaint. In so doing, the Court stated: 'Plaintiffs have adequately stated Exchange Act claims by pleading scienter [knowledge of wrongdoing] through defendants' unusual stock sales and by plausibly alleging loss causation between the corrective announcement and stock price drop. Plaintiffs have also stated Securities Act claims against NAPCO and the underwriter defendants.' 'Taking the well-pleaded facts as true, there is no question that plaintiffs have adequately pled scienter. First, the stock sales were highly unusual in timing and amount. As to amount, the total proceeds of over $108 million from stock sales by the officer defendants weigh in favor of a motive. . . . And the officer defendants sold hefty percentages of their holdings – 48.5% for Soloway and 45.5% for Buchel.' What To Do Now: If you have held NAPCO shares since prior to November 7, 2022, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. If you would like to learn more about this matter, please visit contact Joshua H. Grabar at [email protected], or call 267-507-6085. Treace Medical Concepts, Inc. (NASDAQ: TMCI) If you have held Treace Medical Concepts (NASDAQ: TMCI) shares continuously since prior to May 8, 2023, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit or contact Joshua H. Grabar at [email protected] or call 267-507-6085 to learn more. Why? A recently filed securities class action complaint alleges that, Treace Medical Concepts, Inc. (NASDAQ: TMCI), via certain of its officers, made materially false and/or misleading statements and failed to disclose adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System; (2) as a result, Treace Medical's revenue declined, and the Company needed to accelerate its plans to offer a product that served as an alternative to osteotomy (a surgical procedure involving the cutting and realignment of a bone to improve its position or function); and (3) Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. What You Can Do Now: Current Treace shareholders who have held Treace shares since prior to May 8, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit contact us at [email protected], or call 267-507-6085. #Treace $TMCI Virtu Financial Inc. (NASDAQ: VIRT) Class Action Survives Motion to Dismiss: A federal securities fraud class action complaint alleging that Virtu Financial Inc. (NASDAQ: VIRT), and certain of its officers failed to disclose to investors that it had improper safeguards in place for sensitive trader information, has survived a motion to dismiss. Virtu shareholders who have continuously held Virtu shares since prior to November 7, 2018, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Learn more or join by clicking contact Joshua H. Grabar at [email protected], or call 267-507-6085. WHY: A securities fraud class action complaint alleges that Virtu Financial (NASDAQ: VIRT), via certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) the Company maintained deficient policies and procedures with respect to its information access barriers; (ii) accordingly, Virtu had overstated the Company's operational and technological efficacy as well as its capacity to block the exchange of confidential information between departments or individuals within the Company; (iii) the foregoing deficiencies increased the likelihood that the Company would be subject to enhanced regulatory scrutiny; and (iv) as a result, Defendants' public statements were materially false and/or misleading at all relevant times. On March 17, 2025, a federal Court determined that key allegations were sufficiently pled to survive defendants' motion to dismiss. According to the Court's Order, 'essentially anyone at Virtu, including its proprietary traders' could directly access this material non-public information from at least January 2018 through April 2019, and to do so, Virtu traders only needed to use a 'widely known and frequently shared username and password.' WHAT YOU SHOULD DO NOW: If you are a current Virtu shareholder who has held Virtu stock since on or before November 7, 2018, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever. If you would like to learn more about this matter, you are encouraged visit contact Joshua H. Grabar at [email protected] or call 267-507-6085. $VIRT #VirtuFinancial Attorney Advertising Disclaimer Contact: Joshua H. Grabar, Esq. Grabar Law Office One Liberty Place 1650 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: 267-507-6085 Email: [email protected]
Associated Press
14-03-2025
- Business
- Associated Press
Notice to Long-Term Shareholders of Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf
Mercury Systems, Inc. (NASDAQ: MRCY) Class Action Survives Motion to Dismiss: A securities fraud class action complaint against Mercury Systems, Inc. (NASDAQ: MRCY) has survived defendants' attempts to dismiss the complaint. Grabar Law Office is now investigating claims on behalf of long-term Mercury Systems shareholders. The investigation concerns whether certain officers and directors of Mercury Systems have breached their fiduciary duties owed to the company. Current Mercury Systems (NASDAQ: MRCY) shareholders who have held shares since prior to February 3, 2021, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. To learn more or join click here: WHY: A recently filed securities fraud class action complaint has now partially survived defendants' attempts to dismiss that complaint. The underlying complaint alleges that Mercury Systems, through certain of its officers and directors, used acquisitions and improper revenue recognition practices to mask its inability to grow organically. The complaint further alleges that Defendants repeatedly misled investors to believe that their growth was organic by misrepresenting several elements of Mercury's business, including by hiding that Mercury had switched from 'point-in-time' to 'long-term contracts' in order to improperly boost reported revenues and that several of Mercury's projects were in significant distress, including projects related to Mercury's acquisition of Physical Optics Corporation. Finally, the Complaint alleges Mercury also lied to investors about its strategic growth initiative, 1MPACT, which was designed to improve profit margins but unbeknownst to investors was used to disguise regular expenses as restructuring costs, enabling Mercury to claim that recurring expenses were one-time costs. On February 20, 2025, a Federal Court determined that certain key allegations in the plaintiff's underlying securities fraud class action complaint were adequately pleaded to survive defendants attempts to dismiss the complaint. WHAT YOU CAN DO NOW: If you have held Mercury Systems shares since prior to February 3, 2021, and would like to learn more about this matter, you are encouraged to visit contact Joshua H. Grabar at [email protected], or call us at 267-507-6085. $MRCY #MercurySystems Methode Electronics, Inc. (NYSE: MEI): Grabar Law Office is investigating claims on behalf of Methode Electronics Inc. (NYSE: MEI) shareholders. The investigation concerns whether certain officers of Methode Electronics have breached the fiduciary duties they owed to the company. Current Methode Electronics, Inc. (NYSE: MEI) shareholders who have held Methode Electronics shares since prior to June 23, 2022, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award - all at no cost to them whatsoever. To learn more visit: contact Joshua Grabar at [email protected], or call 267-507-6085. Why: A recently filed underlying securities fraud class action complaint alleges that Methode Electronics, via certain of its officers and directors, made false and/or misleading statements and/or failed to disclose that: (i) Methode Electronics had lost highly skilled and experienced employees during the COVID-19 pandemic necessary to successfully complete Methode Electronics' transition from its historic low mix, high volume production model to a high mix, low production model at its Monterrey facility; (ii) Methode Electronics' attempts to replace its General Motors center console production with more diversified, specialized products for a wider array of vehicle manufacturers and OEMs, in particular in the electric vehicle ('EV') space, had been plagued by production planning deficiencies, inventory shortages, vendor and supplier problems, and, ultimately, botched execution of Methode Electronics' strategic plans; (iii) Methode Electronics' manufacturing systems at its critical Monterrey facility suffered from a variety of logistical defects, such as improper system coding, shipping errors, erroneous delivery times, deficient quality control systems, and failures to timely and efficiently procure necessary raw materials; (iv) Methode Electronics had fallen substantially behind on the launch of new EV programs out of its Monterrey facility, preventing Methode Electronics from timely receiving revenue from new EV program awards; and (v) as a result, Methode Electronics was not on track to achieve the 2023 diluted earnings-per-share guidance or the 3-year 6% organic sales compound annual growth rate represented to investors and such estimates lacked a reasonable factual basis. Current Methode Electronics shareholders who have held Methode Electronics stock since prior to June 23, 2022, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit contact Joshua Grabar at [email protected], or call 267-507-6085. #Methode #MethodeElectronics $MEI Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office is investigating claims on behalf of Monolithic Power Systems, Inc. (NASDAQ: MPWR) shareholders. The investigation concerns whether certain officers and directors of Monolithic have breached their fiduciary duties owed to the company. Current Monolithic (NASDAQ: MPWR) shareholders who have held shares of the Company's stock since prior to February 8, 2024, can seek corporate reforms, the return of funds back to the company, and potentially a court approved incentive award if appropriate, at no cost to them whatsoever. Click here to learn more: WHY: A recently filed securities fraud class action Complaint alleges that, Monolithic Power Systems, Inc. (NASDAQ: MPWR), via certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) Monolithic's voltage regulator modules and power management integrated circuits were suffering from significant performance and quality control issues; (ii) these defects had, in turn, negatively impacted the performance of certain products offered by Nvidia in which such products were used; (iii) Monolithic had failed to adequately address and resolve known issues affecting the performance of the power management solutions Monolithic supplied to Nvidia; (iv) Monolithic's relationship with Nvidia - the Company's most important customer - had been irreparably damaged due to the significant performance and quality control problems affecting the products it supplied to Nvidia and Monolithic's failure to adequately address such issues; and (v) as a result of the above, Monolithic was acutely exposed to material undisclosed risks of significant business, financial, and reputational harm. WHAT YOU CAN DO NOW: If you have held Monolithic shares since prior to February 8, 2024, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever. Please visit contact Joshua Grabar at [email protected] or Mia Heller at [email protected], or call us at 267-507-6085. #MonolithicPower #MPWR $MPWR Sage Therapeutics, Inc. /(NASDAQ: SAGE): Grabar Law Office is investigating claims on behalf of Sage Therapeutics, Inc. (NASDAQ: SAGE) shareholders. The investigation concerns whether certain officers and directors of Sage Therapeutics breached the fiduciary duties they owed to the company. If you are a current Sage Therapeutics, Inc. (NASDAQ: SAGE) shareholder who purchased or acquired Sage Therapeutics shares prior to April 12, 2021, you can seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit email [email protected], or call us at 267-507-6085. WHY? An underlying securities fraud class action complaint alleges that Sage Therapeutics, via certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that Defendants made false and/or misleading statements and/or failed to disclose that: (i) zuranolone was less effective in treating MDD than Defendants had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone's clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating MCI due to PD than Defendants had led investors to believe; (iv) accordingly, SAGE-718's clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated; (v) SAGE-324 was less effective in treating ET than Defendants had led investors to believe; (vi) accordingly, SAGE-324's clinical, regulatory, and commercial prospects as a treatment for ET were overstated; and (vii) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times. Contact: Joshua H. Grabar, Esq. Grabar Law Office One Liberty Place 1650 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: 267-507-6085
Associated Press
10-03-2025
- Automotive
- Associated Press
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf as Certain Class Actions Move Forward
Driven Brands Holdings, Inc. (NASDAQ: DRVN) Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of long-term Driven Brands Holdings, Inc. (NASDAQ: DRVN) shareholders. The investigation concerns whether certain officers of the company have breached their fiduciary duties they owed to the company. If you have held Driven Brands (NASDAQ: DRVN) shares continuously since prior to October 27, 2021, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit or contact Joshua H. Grabar at [email protected] or call 267-507-6085 to learn more. WHY: An underlying securities fraud class action complaint alleges that Driven Brands, through certain of its officers and directors, made numerous materially false and misleading statements and omissions pertaining to: (i) Driven Brands' ability to efficiently and effectively integrate a high volume of acquired businesses, including statements related to the status of integrating its U.S. auto glass businesses; and (ii) the performance and competitive position of Driven Brands' car wash business segment. On February 20, 2025, a Federal Court determined that the allegations in the plaintiff's underlying securities fraud class action complaint were adequately pleaded to survive defendants attempts to dismiss the complaint. WHAT TO DO NOW: Current Driven Brands shareholders who have held Driven Brands shares since prior to October 27, 2021, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter at no cost to you, you are encouraged to visit contact Joshua H. Grabar at [email protected] or call 267-507-6085. $DRVN #DrivenBrands Mercury Systems, Inc. (NASDAQ: MRCY) Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of Mercury Systems, Inc. (NASDAQ: MRCY) shareholders as securities fraud class action complaint partially survives motion to dismiss. The investigation concerns whether certain officers and directors of Mercury Systems have breached their fiduciary duties owed to the company. Current Mercury Systems shareholders who have held shares since prior to February 3, 2021, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. To learn more or join click here: WHY: A recently filed securities fraud class action complaint has now partially survived defendants' attempts to dismiss that complaint. The underlying complaint alleges that Mercury Systems, through certain of its officers and directors, used acquisitions and improper revenue recognition practices to mask its inability to grow organically. The complaint further alleges that Defendants repeatedly misled investors to believe that their growth was organic by misrepresenting several elements of Mercury's business, including by hiding that Mercury had switched from 'point-in-time' to 'long-term contracts' in order to improperly boost reported revenues and that several of Mercury's projects were in significant distress, including projects related to Mercury's acquisition of Physical Optics Corporation. Finally, the Complaint alleges Mercury also lied to investors about its strategic growth initiative, 1MPACT, which was designed to improve profit margins but unbeknownst to investors was used to disguise regular expenses as restructuring costs, enabling Mercury to claim that recurring expenses were one-time costs. On February 20, 2025, a Federal Court determined that certain key allegations in the plaintiff's underlying securities fraud class action complaint were adequately pleaded to survive defendants attempts to dismiss the complaint. WHAT YOU CAN DO NOW: If you have held Mercury Systems shares since prior to February 3, 2021, and would like to learn more about this matter, you are encouraged to visit contact Joshua H. Grabar at [email protected], or call us at 267-507-6085. $MRCY #MercurySystems Playstudios, Inc. (NASDAQ: MYPS) Class Action Survives Motion to Dismiss and Settles: Grabar Law Office is investigating claims on behalf of Playstudios, Inc. (NASDAQ: MYPS) shareholders. The investigation concerns whether certain officers and directors of Playstudios breached the fiduciary duties they owed to the company as class action reaches settlement. If you are a current Playstudios shareholder who purchased or acquired Playstudios shares prior to August 11, 2021 (including by way of exchange of publicly listed Acies shares), and still hold shares today, you can seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit contact Joshua Grabar at [email protected], or call us at 267-507-6085 WHY? A federal securities fraud class action has survived a motion to dismiss and has now reached a settlement. On or about February 1, 2021, Playstudios ('Old Playstudios'), a privately-held gaming company, and Acies Acquisition Corp., a 'blank check' special purpose acquisition company ('SPAC'), entered into a merger agreement to form Playstudios, Inc. The underlying class action complaint was brought on behalf of a class consisting of all persons and entities other who: (1) purchased, or otherwise acquired securities of Playstudios, Inc. ('Playstudios') during the Class Period (August 11, 2021 and May 5, 2022) ; (2) held common stock of Acies Acquisition Corp. as of May 25, 2021, and were eligible to vote at Acies' June 16, 2021 special meeting who exchanged their shares of Acies stock for shares of Playstudios stock pursuant to the merger of Acies and Old Playstudios; or (3) purchased or otherwise acquired Playstudios common stock pursuant to or traceable to the Acies' Registration Statement and Proxy Statement issued in connection with the June 2021 merger. The Complaint alleges that as a result of Defendants' wrongful conduct and fraudulent statements to the market, shareholders paid artificially inflated prices for their Playstudios securities and suffered substantial losses and damages thereby. On March 31, 2024, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss, finding that 'all the statements identified within the Amended Complaint are actionable' but for one. On March 6, 2025, a settlement of the securities fraud class action was reached. WHAT YOU CAN DO NOW: If you purchased Playstudios shares prior to August 11, 2021 (including by way of exchange of publicly-listed Acies shares), and still hold shares today, you are encouraged to visit contact Joshua Grabar at [email protected], or call 267-507-6085. You may be able to seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Playstudios $MYPS Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office is investigating claims on behalf of Sage Therapeutics, Inc. (NASDAQ: SAGE) shareholders. The investigation concerns whether certain officers and directors of Sage Therapeutics breached the fiduciary duties they owed to the company. If you are a current Sage Therapeutics, Inc. (NASDAQ: SAGE) shareholder who purchased or acquired Sage Therapeutics shares prior to April 12, 2021, you can seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit email [email protected], or call us at 267-507-6085. WHY? An underlying securities fraud class action complaint alleges that Sage Therapeutics, via certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that Defendants made false and/or misleading statements and/or failed to disclose that: (i) zuranolone was less effective in treating MDD than Defendants had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone's clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating MCI due to PD than Defendants had led investors to believe; (iv) accordingly, SAGE-718's clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated; (v) SAGE-324 was less effective in treating ET than Defendants had led investors to believe; (vi) accordingly, SAGE-324's clinical, regulatory, and commercial prospects as a treatment for ET were overstated; and (vii) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times. WHAT YOU CAN DO NOW: If you purchased Sage Therapeutics shares prior to April 12, 2021 and still hold shares today, you are encouraged to visit contact Joshua Grabar at [email protected], or call 267-507-6085. You may be able to seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #SageTherapeutics $SAGE Contact: Joshua H. Grabar, Esq. Grabar Law Office One Liberty Place 1650 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: 267-507-6085
